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Abstract
Type I interferons (IFN/) are an important part of innate immunity to viral infections because they induce an antiviral response and
limit viral replication until the adaptive response clears the infection. Since the nonstructural proteins of several paramyxoviruses inhibit the
IFN/ response, we chose to explore the role of the C protein of measles virus (MV) in such inhibition. Previous studies have suggested
that the MV C protein may serve as a virulence factor, but its role in the pathogenesis of MV remains undefined. In the present study, a
recombinant MV strain that does not express the C protein (MV C) and its parental strain (Ed Tag) were used. Growth of MV C was
restricted in human peripheral blood mononuclear cells and HeLa cells, but in the presence of neutralizing antibodies to IFN/, MV C
produced titers that were equivalent to those of Ed Tag. In addition, expression of the MV C protein from plasmid DNA inhibited the
production of an IFN/ responsive reporter gene and, to a lesser extent, inhibited an IFN responsive reporter gene. The ability of the MV
C protein to suppress the IFN/ response was confirmed using a biologic assay. After IFN stimulation, HeLa cells infected with Ed Tag
produced five-fold less IFN/ than cells infected with MV C. While the mechanism of inhibition remains unclear, these data suggest
that the MV C protein plays an important role in the pathogenesis of MV by inhibiting IFN/ signaling.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Measles virus (MV) is a member of the Morbillivirus
genus within the subfamily Paramyxovirinae of the family
Paramyxoviridae. Measles infection is manifest as fever,
cough, coryza, conjunctivitis, and a characteristic maculo-
papular rash. Once a common childhood illness, measles is
now successfully controlled in many areas by vaccination,
though sporadic outbreaks still occur. In developing coun-
tries where vaccination coverage is low, and malnutrition,
crowding, and other infectious diseases are prevalent, mea-
sles is responsible for approximately 770,000 deaths annu-
ally, making it the leading cause of death among children by
a vaccine-preventable illness (WHO, 2002). Immunosup-
pression resulting from measles infection can last up to 3
months, leading to secondary infections that are the primary
cause of mortality (Griffin, 2001).
Viruses in the subfamily Paramyxovirinae express one
or two nonstructural proteins, C and/or V, from the phos-
phoprotein (P) gene. In addition to the P protein, the P genes
of the Respiroviruses, Morbilliviruses, and Henipaviruses
express one or more C proteins from overlapping reading
frames and V is expressed from an edited mRNA. The P
genes of the Rubulaviruses express P and V (Griffin, 2001;
Lamb and Kolakofsky, 2001). The single C protein of MV
is 186 amino acids in size and is encoded by an open
reading frame that begins 22 nucleotides downstream of the
P gene start codon (Bellini et al., 1985).
Several studies have shown that the nonstructural pro-
teins of the paramyxoviruses inhibit the type I interferon
(IFN/) response (Didcock et al., 1999a; Garcin et al.,
1999; Gao et al., 2001; Gotoh et al., 2001, 2002; Parisien et
al., 2001; Young et al., 2001). The type I IFNs, which
consist primarily of IFN and IFN, are important compo-
nents of the innate immune response. These potent inflam-
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matory cytokines are produced by virally infected cells and
serve as an early response to inhibit viral replication by
preventing the infection of neighboring cells and initiating
the adaptive immune response (Stark et al., 1998; Good-
bourn et al., 2000; Sen and Biron, 2001). IFN signaling is
triggered by binding of IFN/ to the ubiquitous IFN/
receptor (IFNR), resulting in upregulation of IFN/ re-
sponsive genes, including double-stranded RNA-dependent
protein kinase (PKR), 2-5-oligoadenylate synthetase, ma-
jor histocompatibility class I (MHC I), and the Mx family of
proteins. In addition to generating an antiviral state in the
cell, IFN/ are known to have potent immunomodulatory
effects such as enhancement of dendritic cell maturation,
activation macrophages, and extension of T cell life spans
(Stark et al., 1998; Goodbourn et al., 2000; Sen and Biron,
2001).
Previous reports have shown that IFN/ induction by
MV was dependant on passage history of the virus and the
cell type tested (Volckaert-Vervliet and Billiau, 1977;
Volckaert-Vervliet et al., 1978; Naniche et al., 2000), and
the MV V protein has been shown to inhibit IFN/ sig-
naling (Palosaari et al., 2003; Takeuchi et al., 2003). Since
the MV C protein has been shown to be a virulence factor
(Valsamakis et al., 1998; Escoffier et al., 1999; Mrkic et al.,
2000; Patterson et al., 2000) and to bind to the IFNR along
with the MV V protein (Yokota et al., 2003), we explored
the role that this protein plays in the inhibition of IFN/
responses by MV. Here we report that the MV C protein
inhibited the production of IFN/ by human cells and
inhibited IFN/ signaling.
Results
The replication of MV C is restricted in cells of human
origin
The two viruses used in this study were derived from an
infectious clone of measles virus. The infectious clone of Ed
Tag is based on the prototype Edmonston sequence and
contains three unique nucleotide substitutions in noncoding
regions that serve as genetic markers. MV C was derived
from the infectious clone of Ed Tag and contains additional
nucleotide substitutions to prevent expression of the C pro-
tein (Radecke and Billeter, 1996; Schneider et al., 1997). To
evaluate the relative replicative abilities of MV C and Ed
Tag, various cell types were infected at a multiplicity of
infection (m.o.i.) of 0.1 and viral titers were measured after
5 days of incubation. Vero cells, which cannot produce
IFN/ (Mosca and Pitha, 1986), are derived from African
green monkey kidney fibroblasts and are commonly used
for virus propagation. CV-1 cells are an IFN/ competent
(Thacore et al., 1990) simian fibroblast cell line, and B95-8a
cells are an Epstein–Barr virus transformed, marmoset B
cell line that is the preferred cell line for isolation of MV
from clinical specimens (Kobune et al., 1990). Ed Tag and
MV C produced equivalent titers in the nonhuman pri-
mate cell lines Vero, B95a, and CV-1 (Fig. 1).
In HeLa cells and primary PBMC, both of which are
IFN/ competent and of human origin, MV C produced
titers that were approximately 2–3 logs lower than the titers
produced by Ed Tag (Fig. 1), and similar results were
obtained from primary human lung microvascular endothe-
lial cells (HLMEC) (data not shown). The titers obtained
after infection of human PBMC with MV C and Ed Tag
were similar to those previously reported by Escoffier et al.
(1999). Taken together, these results show that replication
of MV C was restricted in cells of human origin that are
IFN/ competent; however the restriction was not ob-
served in IFN/ competent cells of simian origin.
Growth of MV C in human cells can be rescued by
addition of antibodies to IFN/
To determine if IFN/ were responsible for the re-
stricted growth of MV C in the cells of human origin,
peripheral blood mononuclear cells (PBMC) and HeLa cells
were infected at an m.o.i. of 0.1, with Ed Tag or MV C in
the presence of normal rabbit serum or neutralizing anti-
bodies to IFN/ and incubated for 48 h. In the presence of
anti-IFN/ antibodies, titers of MV C were equivalent to
those of Ed Tag (Fig. 2). The growth of MV C was
restricted in the cultures treated with normal rabbit serum,
while the titers of Ed Tag were not affected (Fig. 2). The
anti-IFN/ antibodies were tested over a range of concen-
trations and the results in Fig. 2 were obtained by using the
highest concentration of antibodies that rescued the growth
of MV C. These results suggested that the reduced growth
of MV C in human cell types was due to the antiviral
effects of the type I IFNs.
MV reduces IFN/ production following IFN stimulation
of infected cells
Since neutralizing IFN/ rescued the growth of MV
C in human cells, we tested the ability of HeLa cells that
were infected with Ed Tag or MV C to produce IFN/ in
Fig. 1. The replication of MV C is restricted in cells of human origin.
Vero, CV-1, B95-8a, human PBMC, and HeLa cells were infected with
MV C (white bars) or ED Tag (black bars). After 5 days of incubation,
the viral titers were determined by plaque assay on Vero cells. Data are the
average of two experiments.
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response to recombinant IFN (rIFN) stimulation. The 4-h
stimulation with rIFN was necessary because this assay
was not sufficiently sensitive to detect IFN/ production
by unstimulated, MV-infected HeLa cells. Attempts were
made to measure IFN production in infected cells by using
flow cytometry or EIA, but these experiments were unsuc-
cessful. Supernatants from the infected HeLa cells were
transferred in two-fold serial dilutions to Vero cells where
the presence of IFN/ was measured as protection from
encephalomyocarditis (EMC) virus-mediated lysis.
Ed Tag blocked the production of IFN/ by HeLa cells
when stimulated with rIFN, while HeLa cells infected with
MV C produced IFN/ after rIFN stimulation. Super-
natants from HeLa cells infected with MV C, or treated
with a mock-infected Vero cell lysate, contained signifi-
cantly more IFN/ than supernatants from HeLa cells
infected with Ed Tag (Fig. 3). HeLa cells treated with an
uninfected Vero cell lysate produced IFN/ in response to
rIFN stimulation, indicating that differences in the IFN/
response were a result of viral infection and not a response
to a component of the inoculum. In addition, supernatant
medium from HeLa cells infected with MV C that was
incubated with antibodies to IFN/ lost the ability to
prevent the EMC-mediated lysis. Vero cells were inoculated
with HeLa cell supernatants and incubated for 5 days to
demonstrate that they did not contain detectable quantities
of MV as measured by plaque formation. These results
suggest that not only can the growth of MV C be inhibited
by IFN/, but MV C has lost the ability to inhibit the
production of IFN/ in stimulated cells.
Viral stocks containing high levels of defective interfering
particles do not inhibit the IFN/ response
Our data indicating that MV C protein inhibits the
IFN/ response were obtained by using viral stocks that
were prepared in Vero cells. Previous work by Naniche et
al. (2000) showed that strains of MV that had been
isolated on PBMC or B95a cells induced 10 times more
IFN/ after they were passaged in Vero cells, suggest-
ing that host cell passage had selected for viruses that
differed in their ability to induce IFN/. In our exper-
iments Ed Tag and MV C were plaque purified before
stocks were prepared by low m.o.i. of Vero cells. Since
passage of MV in Vero cells at high m.o.i. results in the
accumulation of defective interfering particles (DIs)
(Whistler et al., 1996), interference assays were used to
confirm the absence of DI activity in the viral stocks used
in our experiments.
To test the effect of DIs on IFN/ induction, a DI
containing stock of Ed Tag (Ed Tag-DI) was produced by
serial undiluted passage in Vero cells. This stock had an
interference activity that reduced titers of standard virus by
2 logs. Supernatants from IFN-stimulated HeLa cells in-
fected with Ed Tag-DI contained significantly more IFN/
than supernatants from Ed Tag infected Vero cells, or mock-
infected Vero cells. The inhibition of IFN/ induction that
was observed after infection with plaque-purified stocks of
Ed Tag was not observed when the stock contained detect-
able interference activity (Fig. 3). These data suggest that
the inability of Vero passaged viruses to inhibit IFN/ is
dependent on the presence of DIs and is not a result of host
cell selection of viruses.
Fig. 3. HeLa cells infected with MV C and Ed Tag-DI produce more
IFN/ in response to rIFN stimulation than cells infected with Ed Tag.
Data represent the highest dilution of the HeLa cell supernatant that
inhibited EMC mediated lysis. Error bars represent one standard deviation
from the mean triplicate wells (* indicates statistical significance, Student’s
t test).
Fig. 2. Rescue of growth of MV C in human PBMC (A) and HeLa cells
(B). Cells were infected in the continuous presence of antibodies to IFN/
or normal rabbit serum. Cells were harvested at 48 h postinfection and viral
titers were determined by plaque assay in Vero cells. Black bars represent
the average titer obtained from triplicate samples (standard deviation).
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The MV C protein blocks induction of IFN/ and IFN
responsive reporter genes
To test the effect of the MV C protein on induction of an
IFN/ responsive gene, the MV C protein was expressed
in Vero cells that were transfected with plasmids encoding
the firefly luciferase gene under the control of an ISRE.
Expression of the MV C protein inhibited IFN/-induced
luciferase production by more than 90% (Fig. 4A) relative
to cells transfected with the plasmid vector alone or a
plasmid expressing the irrelevant viral protein, the glyco-
protein of Nipah virus. In addition, cells that were not
stimulated with rIFN produced much lower levels of lu-
ciferase, indicating that the ISRE-dependent gene expres-
sion was restricted to stimulated cells. These results suggest
that expression of the MV C protein, in the absence of other
MV proteins, can inhibit the induction of IFN/ respon-
sive genes.
Since the type I and type II IFN signaling pathways share
some components, the effect of the MV C protein on IFN
signaling was also tested using a similar luciferase reporter
plasmid containing an IFN activating sequence (GAS) that
is IFN responsive. Expression of the MV C protein inhib-
ited luciferase production by 50% from this plasmid com-
pared with production by cells that were transfected with the
control vector plasmid alone. These findings were not due to
a global downregulation of transcription or translation since
Western blots showed no differences in the amount of
cellular actin present in infected PBMC. The inhibition of
both types of IFN suggested the possible involvement of
STAT1, since this molecule is critical in both signaling
pathways.
STAT1 is present at higher levels in MV C infected
cells than in those infected with Ed Tag
Since other paramyxoviruses target STAT1 for degrada-
tion, Western blots were performed to measure STAT1
levels in PBMC infected with Ed Tag or MV C. The
amounts of STAT1 present in rIFN-stimulated and un-
stimulated mock-infected PBMC were compared with
STAT1 levels in unstimulated cells infected with either Ed
Tag or MV C. STAT1 levels were measured by lumines-
cence and normalized to cellular actin levels. Relative to
levels in the unstimulated, mock-infected PBMC, MV C
infected PBMC expressed higher levels of STAT1 (48.5%)
than Ed Tag infected PBMC (14.3%) (Fig. 5). Cellular actin
levels were equivalent in all of the cultures, and flow cyto-
metric analysis to detect the MV N protein indicated that
approximately 70% of the cells were infected with either Ed
Tag or MV C (data not shown). The activation state of
STAT1 in these cells is unknown; however, STAT1 is a
critical protein in both type I and type II IFN signaling
pathways, and these data suggest that in human PBMC, the
absence of the MV C protein correlates with higher levels of
STAT1.
Since the increased STAT1 levels found in MV C
infected PBMC could be due to either STAT1 degradation
by the MV C protein or an increase in STAT1 levels due to
IFN/ production and signaling, Western blots were per-
formed on Ed Tag and MV C infected Vero cells. Since
Vero cells are not able to produce IFN/, STAT1 levels
will not change in response to IFN/ produced by neigh-
boring cells. STAT1 was present at similar levels in both Ed
Tag infected and Vero lysate treated cells, indicating that
the measles infection does not result in the degradation of
STAT1. When normalized to cellular actin levels, STAT1
was present at slightly higher levels in MV C infected
cells than in the cells infected with Ed Tag (Fig. 5C).
Discussion
This article provides direct evidence that the MV C
protein inhibits IFN signaling and the ability to respond to
IFN stimulation. This is also the first report of IFN/
inhibition by the C protein of a Morbillivirus. The results
presented here are consistent with those of previous studies
suggesting that MV C is a virulence factor. Relative to Ed
Fig. 4. The MV C protein inhibits expression of interferon-responsive
reporter genes. Vero cells were transfected with plasmids containing the
luciferase reporter gene under the control of an IFN/ responsive pro-
moter (A) or an IFN responsive promoter (B), the plasmid constitutively
expressing renilla luciferase, and either the plasmid vector control, plasmid
expressing MV C, or plasmid expressing Nipah G. Twenty-four hours later,
the cells were stimulated with 100 U rIFN. Expression levels of the firefly
luciferase reporter gene were normalized to the expression levels of the
constitutively expressed renilla luciferase reporter gene to control for
transfection efficiency. Results are expressed as a percentage of firefly
luciferase expression relative to the positive control (vector alone).
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Tag, MV C showed reduced growth in human thymus
tissue that was transplanted into SCID mice as well as
reduced titers and mortality in YAC-CD46 transgenic mice
and IFNR/, CD46 transgenic mice (Valsamakis et al.,
1998; Mrkic et al., 2000; Patterson et al., 2000). The C
protein is not required for viral growth in Vero cells (Ra-
decke and Billeter, 1996; Schneider et al., 1997). Interest-
ingly, when MV isolates from the same clinical specimen
but isolated independently in B95a and Vero cells were
sequenced, the Vero cell-passaged virus had a mutation in P
gene that produced a premature stop codon in the reading
frame for the C protein (Takeuchi et al., 2000).
Previous studies had shown that MV C produced titers
that were nearly 3 logs lower than those of Ed Tag in human
PBMC and these reduced titers correlated with reduced
levels of MV mRNA and viral proteins (Escoffier et al.,
1999). Here, we expand on this observation to show that
growth of MV C was restricted in other IFN/ compe-
tent cells of human origin and that growth could be rescued
by addition of antibodies to IFN/.
Our results are consistent with those in numerous other
reports, some dating back more than 40 years, which
showed paramyxoviruses are able to inhibit the type I IFNs
(Valle and Cantell, 1965; Maeno et al., 1966). In particular,
the replication of various strains of MV was inversely cor-
related with IFN/ production (Volckaert-Vervliet and
Billiau, 1977, Volckaert-Vervliet et al., 1978), and 2-5-
oligoadenylate synthetase was poorly induced in measles-
infected neurons (Fujii et al., 1990). More recent reports
showed that wild-type MV suppressed IFN signaling and
impaired Jak1 phosphorylation (Yokota et al., 2003) and
that strains of MV that had only been passaged in B95-8a
cells or PBMC did not induce IFN/ induction in human
PBMC (Naniche et al., 2000), but induced IFN/ follow-
ing passage in Vero cells. DIs can accumulate in as few as
two to three passages in Vero cells (Calain and Roux, 1988;
Whistler et al., 1996), and our results showed that stocks
containing high levels of interference activity consistently
lost the ability to inhibit IFN/ induction. In this article,
plaque-purified viral stocks with no measurable interference
activity were used to test the relative abilities of the Ed Tag
and MV C viruses to inhibit the IFN/ response.
The results presented here contribute to a growing body
of evidence indicating that the nonstructural proteins en-
coded by the P genes of paramyxoviruses function as viru-
lence factors by inhibiting the production of and cellular
response to the type I IFNs. The C proteins of Sendai virus
(SeV) have many functions, one of which is to inhibit type
I IFN production and responsiveness (Garcin et al., 1999;
Gotoh et al., 1999). In addition, the C proteins of SeV
prevented accumulation of STAT1 and suppressed the in-
duction of STAT2, IRF-9, and PKR (Gotoh et al., 1999).
The SeV C proteins altered the phosphorylation and dephos-
phorylation of STAT1 and partially inhibited phosphoryla-
tion of Tyk2 (Komatsu et al., 2002; Saito et al., 2002).
Expression SeV C proteins inhibited expression of IFN/
responsive reporter genes (Garcin et al., 2000), though con-
flicting data exist as to which of the SeV C proteins was
responsible for the inhibition (Garcin et al., 2001, 2002;
Kato et al., 2001). In the Rubulaviruses, which do not
express a C protein, the V protein inhibits the type I IFN
response. The V protein of SV5 reduced STAT 1 levels and
this effect was abolished by proteosome inhibitors (Didcock
et al., 1999b). SV5 V, STAT1, and STAT2, together with
unidentified proteins, formed a complex that targeted STAT
1 for degradation (Young et al., 2001; Parisien et al., 2002a,
2002b). The V protein of mumps virus (MuV) also degraded
STAT1 and binding of the MuV V protein to STAT1 led to
Fig. 5. Increased levels of STAT1 are detected in cells infected with MV C compared to Ed Tag. PBMC were infected with Ed-Tag or MV C at an m.o.i.
of 1 and cell lysates were harvested at 24 h postinfection. STAT1 was detected by Western blot with STAT1 specific antibodies. Chemilumenesence signals
were measured by using X-ray film (A) and directly with a CCD camera (B). The amount of STAT1 expressed was measured as luminescence and calculated
as a ratio of STAT1 expression to actin expression. The results are also shown as a percentage relative to the amount of STAT1 detected in mock-infected
control cells (B). The experiment was repeated in Vero cells (C) to confirm that measles infection did not result in the degradation of STAT1.
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its ubiquitation (Kubota et al., 2002; Yokosawa et al., 2002).
While SV5 and MuV promote degradation of STAT1, the V
protein of human parainfluenza virus-2 inhibited type I IFN
by binding STAT2 and targeting it for degradation (Young
et al., 2000; Parisien et al., 2001b, 2002; Andrejeva et al.,
2002). The Nipah virus V protein bound STAT1 and
STAT2, forming large complexes that could not translocate
into the nucleus and activate transcription (Rodriguez et al.,
2002). Measles virus also expresses a V protein that also
inhibits IFN/ signaling (Palosaari et al., 2003; Takeuchi
et al., 2003). When constitutively expressed in HeLa cells,
the V protein inhibited tyrosine phosphorylation of both
STAT1 and STAT2 (Takeuchi et al., 2003), but inhibition
of phosphorylation was not observed when the protein was
transiently expressed in cells (Palosaari et al., 2003). The
MV V protein bound STAT1, STAT2, STAT3, and IRF-9
and prevented nuclear accumulation of the STAT molecules
(Palosaari et al., 2003).
The data presented here show that the MV C protein
inhibits the cellular response to IFN/ signaling. Our re-
sults agree with those of previous observations that MV
infection does not result in degradation of STAT1 (Palosaari
et al., 2003; Takeuchi et al., 2003). However, the observa-
tion that IFN/ signaling was not inhibited in HeLa cells
stably expressing the MV C protein (Takeuchi et al., 2003)
differs from our results which were obtained in MV-in-
fected HeLa cells and by IFN/ responsive reporter gene
assays. It is important to note that our data were obtained
using the MV C virus, which expresses a V protein, and
that the relative contributions of the MV C and V proteins
to the inhibition the IFN/ responsiveness in vivo are not
known. Studies to define the mechanism of MV C-mediated
inhibition of IFN/ as well as to evaluate the relative
IFN/ inhibition levels of C proteins from wild-type and
vaccine strains of MV are in progress.
Methods and materials
Cells and viruses
Experiments were performed in the following cell types:
HeLa (ATCC: CCL-2) cells cultured in F12 medium
(Gibco, Grand Island, NY), Vero cells (ATCC: CCL-81)
cultured in modified Eagle’s medium (MEM, Gibco),
B95-8a cells (Kobune et al., 1990) cultured in Dulbecco’s
modified Eagle’s medium (Gibco), CV-1 cells (ATCC:
CCL-70), also cultured in Dulbecco’s modified Eagle’s me-
dium (Gibco), and human PBMC cultured in RPMI medium
1640 (Gibco). All medium was supplemented with 10%
fetal bovine serum (FBS) (Hyclone, Logan, Utah), 100 U/l
Penicillin (Gibco), and 100 U/l Streptomycin (Gibco). The
MEM was also supplemented with 2 mM L-glutamine
(Gibco). All PBMC were from a single donor and were
isolated by centrifugation over a Ficoll–Hypaque gradient.
Plaque-purified virus stocks were prepared in Vero cells
and tested for interference activity as described below. Viral
titers were measured by plaque assay (Rota et al., 1994) in
Vero cells. The MV C virus, which does not express the
C protein, and the Ed Tag virus (Radecke and Billeter,
1996; Schneider et al., 1997) were gifts from Dr. Martin
Billeter. Ed Tag was rescued from an infectious clone that
was based on the sequence of the prototype, Edmonston
strain of MV, and MV C was derived from the infectious
clone for Ed Tag. MV C has two mutations in the C
reading frame, which are silent in the P reading frame, that
eliminate the start codon and insert an extra downstream
stop codon. The presence of the mutations was confirmed by
sequencing and the lack of C protein expression was con-
firmed by using immunofluorescence with rabbit antipeptide
antiserum (Bellini et al., 1985).
Virus stocks were plaque-purified three times in Vero
cells. These parent stocks were then passaged at an m.o.i. of
1.0 three times to generate stocks containing defective in-
terfering particles. The titer of stock was measured by using
a standard plaque assay on Vero cells. Interference was
measured as previously described (Whistler et al., 1996).
Viral stocks containing DI particles inhibited showed 1–2
logs of interference activity.
Viral replication and rescue experiments
B95-8a, CV-1, PBMC, and Vero cells were infected with
Ed Tag or MV C at an m.o.i. of 0.1. Cultures were
incubated for 5 days and harvested as cell lysates by freez-
ing and thawing. Viral titers were determined as described
above.
Human PBMC (1  106), purified as described above,
were infected with MV at an m.o.i. of 0.1 in RPMI con-
taining 10% FBS and 5 g/ml PHA (Sigma, St. Louis, MO),
and either 8 l/ml normal rabbit serum or 4 l/ml antibody
to IFN (Mab413, Chemicon, Temecula, CA) and 800
neutralizing units/ml antibody to IFN (Mab1431, Chemi-
con). Cells were incubated for 2 days before being har-
vested. Viral titers were determined as described above.
HeLa cells in F12 medium containing 5% FBS, 100 U/l of
penicillin, and 100 U/l of streptomycin were infected at an
m.o.i. of 0.1 in the presence of the same antibodies de-
scribed above. The procedure for harvest and measurement,
was as described above. Antibodies have been shown to be
neutralizing by manufacturer and also in our biological
IFN/ assay (J. Shaffer, unpublished observation).
Biologic IFN/ assay
IFN/ production was measured by testing for inhibi-
tion of cell lysis by EMC virus similar to a method previ-
ously described (Yeh et al., 1982). HeLa cells were infected
with MV at an m.o.i. of 0.1, and control cells were treated
with an equivalent volume of an uninfected Vero cell lysate.
The infection continued for 24 h at 37°C, at which time the
supernatants were removed, the cells were washed, and 100
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U recombinant IFN (BioSource International, Camarillo,
CA) was added in 200 l F12. After 1 h at 37°C, the cells
were washed twice with medium, and 200 L F12 medium
containing 2% FBS was added. After 1 h at 37°C, 150 l of
the supernatant was transferred to confluent Vero cells as
two-fold serial dilutions in MEM containing 2% FBS. The
Vero cells were then infected by adding 5000 PFU EMC to
the medium. The infection continued for 24 h at 37°C, and
the cells were fixed and stained with crystal violet (15%
formaldehyde, 2.5% ethanol, 0.65 g crystal violet in 1 L
PBS). Cells were washed with PBS and lysis was detected
by the visible presence or absence of an intact cell mono-
layer in the well.
Measurement of expression of IFN-responsive genes
A plasmid containing the MV C gene under the control
of a CMV promoter, pCMV-C, was made by using RT-PCR
to amplify the P gene from RNA extracted from cells
infected with the Edmonston wild-type strain. The primers
5 gat cga att cca ggc acg cca tgt ca 3 and 5 gat cct cga ggc
tgt agc tac ttc at 3 were designed so that the first 12
nucleotides of the P open reading frame were not amplified.
This amplicon was digested with EcoR1 and XhoI and
ligated into the plasmid vector pCMV (Stratagene, Cedar
Creek, TX). Expression of MV C from this plasmid was
confirmed by performing immunofluorescence assays on
transfected cells and MV C was detected with rabbit anti-
peptide antiserum (Bellini et al., 1985). The pCMV-NipG
construct was used as a control (Harcourt et al., 2000). The
pISRE and pGAS plasmids were gifts from Dr. R.E. Randall
(North Haugh University of St. Andrews, Fife, Scotland).
pISRE encodes the firefly luciferase gene following four
tandem repeats of the interferon stimulation response ele-
ment (ISRE) from the IFN inducible gene 9-27 (King and
Goodbourn, 1998; Didcock et al., 1999a; Garcin et al.,
1999). pGAS contains the minimal thymidine kinase pro-
moter and two tandem repeats of the IFN activating se-
quence (GAS) from the IRF-1 gene (King and Goodbourn,
1998). The pRL-TK plasmid encodes the renilla luciferase
gene constitutively expressed from a thymidine kinase pro-
moter and is used as a transfection control.
Vero cells in 24-well tissue culture plates were trans-
fected using FuGene (Roche, Indianapolis, IN) in MEM
with 2% FBS according to the manufacturer’s protocol and
0.9 g of the plasmids pISRE or pGAS were cotransfected
with 0.05 g pRL-TK (Promega, Madison WI) and 1 g
pCMV-C, pCMV-NipG, or pCMV. Cells were allowed to
recover from transfection for 24–28 h and were stimulated
with 100 U recombinant IFN (BioSource International) for
6 h, and cell lysates were harvested for detection of lucif-
erase. Luciferase production was measured using the Dual
Reporter Luciferase System (Promega) according to the
manufacturer’s protocol. Chemiluminescence was recorded
on a closed circuit digital camera (Alpha Innotech, San
Leandro, CA) and quantified by densitometry. The ratio of
firefly luciferase expressed to the amount of renilla lucif-
erase expressed was calculated to control for transfection
efficiency. Those ratios were then expressed as (experimen-
tal/vector control)  100%.
Western blots
The medium was removed 24 h postinfection from in-
fected, mock-infected, or IFN (500 U) stimulated human
PBMC (1  106 cells) or Vero cells and 500 l RIPA (1%
sodium deoxycholate, 1% Triton X-100, 0.2% SDS, 150
mM NaCI, 50 mM Tris–HCl at pH 7.5) buffer was added.
Cell lysates were subjected to electrophoresis through
4–20% SDS–polyacrylamide gels (Bio-Rad, Hercules, CA),
and then transferred to microporous polyvinylidene difluo-
ride (PVDF) membranes (Roche). The membranes were
incubated in a 5% non-fat milk, 0.01% Tween, 0.01 M PBS
solution before adding primary antibodies. The primary
antibodies, anti-STAT1 clone C-136 (Santa Cruz Biotech-
nology, Santa Cruz, CA) and antiactin (Chemicon) were
used at concentrations of 1:100 and a secondary anti-mouse
IgG1-horseradish peroxidase antibody (Zymed, San Fran-
cisco, CA) was used at a concentration of 1:1000. The
chemiluminescent substrate (KPL, Gaithersburg, MD) was
used according to the manufacturer’s protocol and a radio-
graph was generated by exposing the filter to X-ray film.
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